Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 276

1.

Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.

Procopio G, Bamias A, Schmidinger M, Hawkins R, Sánchez AR, Estevez SV, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Rodriguez CS, Jonasch E.

Clin Genitourin Cancer. 2019 Jun;17(3):e526-e533. doi: 10.1016/j.clgc.2019.01.018.

PMID:
31196680
2.

NCCN Guidelines Updates: Management of Metastatic Kidney Cancer.

Jonasch E.

J Natl Compr Canc Netw. 2019 May 1;17(5.5):587-589. doi: 10.6004/jnccn.2019.5008.

PMID:
31117033
3.

VON HIPPEL-LINDAU DISEASE: Update on Pathogenesis and Systemic Aspects.

Aronow ME, Wiley HE, Gaudric A, Krivosic V, Gorin MB, Shields CL, Shields JA, Jonasch EW, Singh AD, Chew EY.

Retina. 2019 May 14. doi: 10.1097/IAE.0000000000002555. [Epub ahead of print]

PMID:
31095066
4.

Durable complete response in renal cell carcinoma clinical trials.

Pilié PG, Jonasch E.

Lancet. 2019 Jun 15;393(10189):2362-2364. doi: 10.1016/S0140-6736(19)30949-3. Epub 2019 May 9. No abstract available.

PMID:
31079937
5.

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.

Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM.

Eur J Cancer. 2019 Jun;114:67-75. doi: 10.1016/j.ejca.2019.04.003. Epub 2019 May 7.

PMID:
31075726
6.

SETD2 regulates the maternal epigenome, genomic imprinting and embryonic development.

Xu Q, Xiang Y, Wang Q, Wang L, Brind'Amour J, Bogutz AB, Zhang Y, Zhang B, Yu G, Xia W, Du Z, Huang C, Ma J, Zheng H, Li Y, Liu C, Walker CL, Jonasch E, Lefebvre L, Wu M, Lorincz MC, Li W, Li L, Xie W.

Nat Genet. 2019 May;51(5):844-856. doi: 10.1038/s41588-019-0398-7. Epub 2019 Apr 29.

PMID:
31040401
7.

SET-ing the stage for PI3Kβ inhibitor sensitivity in clear cell renal cell carcinoma.

Pilié PG, Jonasch E.

Oncotarget. 2019 Feb 22;10(16):1540-1541. doi: 10.18632/oncotarget.26709. eCollection 2019 Feb 22. No abstract available.

8.

Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).

Schmidinger M, Bamias A, Procopio G, Hawkins R, Sanchez AR, Vázquez S, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E; PRINCIPAL Study Group.

Oncologist. 2019 Apr;24(4):491-497. doi: 10.1634/theoncologist.2018-0787. Epub 2019 Mar 13.

PMID:
30867244
9.

Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma.

Bergerot CD, Battle D, Bergerot PG, Dizman N, Jonasch E, Hammers HJ, George DJ, Bex A, Ljungberg B, Pal SK, Staehler MD.

Front Oncol. 2019 Jan 22;9:11. doi: 10.3389/fonc.2019.00011. eCollection 2019.

10.

Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.

Green YS, Sargis T, Reichert EC, Rudasi E, Fuja D, Jonasch E, Koh MY.

Mol Cancer Res. 2019 May;17(5):1220-1232. doi: 10.1158/1541-7786.MCR-18-1080. Epub 2019 Jan 31.

PMID:
30705246
11.

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.

Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM.

Eur J Cancer. 2018 Nov;104:188-194. doi: 10.1016/j.ejca.2018.08.014. Epub 2018 Oct 28.

PMID:
30380460
12.

Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial.

Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, Robichaux CC, Villarreal MF, Weldon JA, Woodson AH, Pilie PG, Fuller GN, Waguespack SG, Matin SF.

Lancet Oncol. 2018 Oct;19(10):1351-1359. doi: 10.1016/S1470-2045(18)30487-X. Epub 2018 Sep 17.

PMID:
30236511
13.

VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.

Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, Lawrence C, Fan J, Geng J, Liu X, Hu L, Wang J, Liao C, Hong K, Zurlo G, Parker JS, Auman JT, Perou CM, Rathmell WK, Kim WY, Kirschner MW, Kaelin WG Jr, Baldwin AS, Zhang Q.

Science. 2018 Jul 20;361(6399):290-295. doi: 10.1126/science.aap8411.

14.

AKT isoform-specific expression and activation across cancer lineages.

Wang J, Zhao W, Guo H, Fang Y, Stockman SE, Bai S, Ng PK, Li Y, Yu Q, Lu Y, Jeong KJ, Chen X, Gao M, Liang J, Li W, Tian X, Jonasch E, Mills GB, Ding Z.

BMC Cancer. 2018 Jul 16;18(1):742. doi: 10.1186/s12885-018-4654-5.

15.

Pilot study of dovitinib in patients with von Hippel-Lindau disease.

Pilié P, Hasanov E, Matin SF, Woodson AHH, Marcott VD, Bird S, Slack RS, Fuller GN, McCutcheon IE, Jonasch E.

Oncotarget. 2018 May 4;9(34):23390-23395. doi: 10.18632/oncotarget.25171. eCollection 2018 May 4.

16.

Updates to the Management of Kidney Cancer.

Jonasch E.

J Natl Compr Canc Netw. 2018 May;16(5S):639-641. doi: 10.6004/jnccn.2018.0039.

PMID:
29784745
17.

Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.

Krauss T, Ferrara AM, Links TP, Wellner U, Bancos I, Kvachenyuk A, Villar Gómez de Las Heras K, Yukina MY, Petrov R, Bullivant G, von Duecker L, Jadhav S, Ploeckinger U, Welin S, Schalin-Jäntti C, Gimm O, Pfeifer M, Ngeow J, Hasse-Lazar K, Sansó G, Qi X, Ugurlu MU, Diaz RE, Wohllk N, Peczkowska M, Aberle J, Lourenço DM Jr, Pereira MAA, Fragoso MCBV, Hoff AO, Almeida MQ, Violante AHD, Quidute ARP, Zhang Z, Recasens M, Díaz LR, Kunavisarut T, Wannachalee T, Sirinvaravong S, Jonasch E, Grozinsky-Glasberg S, Fraenkel M, Beltsevich D, Egorov VI, Bausch D, Schott M, Tiling N, Pennelli G, Zschiedrich S, Därr R, Ruf J, Denecke T, Link KH, Zovato S, von Dobschuetz E, Yaremchuk S, Amthauer H, Makay Ö, Patocs A, Walz MK, Huber TB, Seufert J, Hellman P, Kim RH, Kuchinskaya E, Schiavi F, Malinoc A, Reisch N, Jarzab B, Barontini M, Januszewicz A, Shah N, Young WF Jr, Opocher G, Eng C, Neumann HPH, Bausch B.

Endocr Relat Cancer. 2018 Sep;25(9):783-793. doi: 10.1530/ERC-18-0100. Epub 2018 May 10.

PMID:
29748190
18.

Renal cell carcinoma brain metastasis with pseudoprogression and radiation necrosis on nivolumab after previous treatment with stereotactic radiosurgery: An illustrative case report and review of the literature.

Lewis GD, Jonasch E, Shah AY, Fuller GN, Farach AM, Butler EB, Teh BS.

Pract Radiat Oncol. 2018 Sep - Oct;8(5):e262-e265. doi: 10.1016/j.prro.2018.03.003. Epub 2018 Mar 10. Review. No abstract available.

PMID:
29706304
19.

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.

Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI.

J Clin Oncol. 2018 Jun 1;36(16):1588-1593. doi: 10.1200/JCO.2017.77.1485. Epub 2018 Apr 11.

PMID:
29641297
20.

BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.

Pan T, Lin SC, Yu KJ, Yu G, Song JH, Lewis VO, Bird JE, Moon B, Lin PP, Tannir NM, Jonasch E, Wood CG, Gallick GE, Yu-Lee LY, Lin SH, Satcher RL.

Neoplasia. 2018 Jan;20(1):32-43. doi: 10.1016/j.neo.2017.11.002. Epub 2017 Nov 27.

21.

Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening.

Han G, Zhao W, Song X, Kwok-Shing Ng P, Karam JA, Jonasch E, Mills GB, Zhao Z, Ding Z, Jia P.

BMC Genomics. 2017 Oct 3;18(Suppl 6):678. doi: 10.1186/s12864-017-4026-6.

22.

Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma.

Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY.

Clin Genitourin Cancer. 2017 Aug 10. pii: S1558-7673(17)30238-0. doi: 10.1016/j.clgc.2017.07.028. [Epub ahead of print]

23.

Effects of tamoxifen on urinary incontinence: Case report and review of literature.

Hasanov E, Hasanov M, Kuria IM, Hasanov R, Rzazade R, Jonasch E, Altundag K.

Medicine (Baltimore). 2017 Aug;96(34):e6785. doi: 10.1097/MD.0000000000006785.

24.

Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.

Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA.

Cancer. 2017 Dec 15;123(24):4823-4831. doi: 10.1002/cncr.30937. Epub 2017 Aug 22.

25.

HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.

Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E.

Cancer Res. 2017 Oct 1;77(19):5313-5326. doi: 10.1158/0008-5472.CAN-17-0986. Epub 2017 Aug 14.

26.

Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma.

Pilié PG, Jonasch E.

Kidney Cancer. 2017 Jul 26;1(1):57-64. doi: 10.3233/KCA-170009.

27.

Recommendations for the Management of Rare Kidney Cancers.

Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A.

Eur Urol. 2017 Dec;72(6):974-983. doi: 10.1016/j.eururo.2017.06.040. Epub 2017 Jul 16. Review.

PMID:
28720391
28.

Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape.

Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, Kawakami F, Trevisan P, Jonasch E, Chow CW, Canales JR, Tamboli P, Tannir N, Wood C, Monzon F, Baggerly K, Varella-Garcia M, Czerniak B, Wistuba I, Mills G, Shaw K, Chen K, Sircar K.

Clin Cancer Res. 2017 Nov 1;23(21):6686-6696. doi: 10.1158/1078-0432.CCR-17-1057. Epub 2017 Jul 14.

29.

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK.

J Clin Oncol. 2017 Sep 10;35(26):2993-3001. doi: 10.1200/JCO.2017.72.2967. Epub 2017 Jun 23.

PMID:
28644771
30.

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R.

J Natl Compr Canc Netw. 2017 Jun;15(6):804-834. doi: 10.6004/jnccn.2017.0100.

PMID:
28596261
31.

Incorporating New Systemic Therapies in Kidney Cancer Treatment.

Jonasch E.

J Natl Compr Canc Netw. 2017 May;15(5S):703-705.

PMID:
28515249
32.

Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.

Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM.

J Urol. 2017 Sep;198(3):530-537. doi: 10.1016/j.juro.2017.04.067. Epub 2017 Apr 11.

33.

Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma.

Rini BI, Gruenwald V, Jonasch E, Fishman MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair AH, Rosbrook B, Hutson TE.

Target Oncol. 2017 Jun;12(3):333-340. doi: 10.1007/s11523-017-0487-4.

PMID:
28361451
34.

Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma.

Leal I, Milbury K, Engebretson J, Matin S, Jonasch E, Tannir N, Wood CG, Cohen L.

Palliat Support Care. 2018 Apr;16(2):146-154. doi: 10.1017/S1478951517000074. Epub 2017 Mar 6.

35.

Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.

Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E.

Clin Genitourin Cancer. 2017 Jun;15(3):363-370. doi: 10.1016/j.clgc.2017.01.010. Epub 2017 Jan 18.

PMID:
28216278
36.

Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.

Msaouel P, Zurita AJ, Huang S, Jonasch E, Tannir NM.

Oncotarget. 2017 Jun 27;8(26):42149-42158. doi: 10.18632/oncotarget.15011.

37.

Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL.

Hasanov E, Chen G, Chowdhury P, Weldon J, Ding Z, Jonasch E, Sen S, Walker CL, Dere R.

Oncogene. 2017 Jun 15;36(24):3450-3463. doi: 10.1038/onc.2016.495. Epub 2017 Jan 23.

38.

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM.

Ann Oncol. 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676.

39.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB.

J Immunother Cancer. 2016 Nov 15;4:81. eCollection 2016.

40.

Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.

Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM.

BJU Int. 2017 Dec;120(6):782-792. doi: 10.1111/bju.13705. Epub 2016 Dec 9.

41.

Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.

Matrana MR, Baiomy A, Campbell M, Alamri S, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Elsayes KM, Tannir NM.

Clin Genitourin Cancer. 2017 Apr;15(2):e205-e208. doi: 10.1016/j.clgc.2016.07.016. Epub 2016 Jul 22.

PMID:
27568124
42.

Dual Chromatin and Cytoskeletal Remodeling by SETD2.

Park IY, Powell RT, Tripathi DN, Dere R, Ho TH, Blasius TL, Chiang YC, Davis IJ, Fahey CC, Hacker KE, Verhey KJ, Bedford MT, Jonasch E, Rathmell WK, Walker CL.

Cell. 2016 Aug 11;166(4):950-962. doi: 10.1016/j.cell.2016.07.005.

43.

Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas.

Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RG, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B.

J Pathol Clin Res. 2015 Jul 7;1(4):212-24. doi: 10.1002/cjp2.23. eCollection 2015 Oct.

44.

Autophagy degrades hypoxia inducible factors.

DePavia A, Jonasch E, Liu XD.

Mol Cell Oncol. 2016 Mar 16;3(2):e1104428. doi: 10.1080/23723556.2015.1104428. eCollection 2016 Mar.

45.

Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.

Rini BI, Tomita Y, Melichar B, Ueda T, Grünwald V, Fishman MN, Uemura H, Oya M, Bair AH, Andrews GI, Rosbrook B, Jonasch E.

Clin Genitourin Cancer. 2016 Dec;14(6):499-503. doi: 10.1016/j.clgc.2016.04.005. Epub 2016 Apr 22.

PMID:
27236772
46.

NCCN Evidence Blocks.

Carlson RW, Jonasch E.

J Natl Compr Canc Netw. 2016 May;14(5 Suppl):616-9.

PMID:
27226499
47.

Treatment of Relapsed Germ Cell Tumors: Time For Something New?

Campbell MT, Jonasch E.

J Oncol Pract. 2016 May;12(5):449-50. doi: 10.1200/JOP.2016.012179. No abstract available.

PMID:
27170695
48.

Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support.

Milbury K, Lopez G, Spelman A, Wood C, Matin SF, Tannir NM, Jonasch E, Pisters L, Wei Q, Cohen L.

Psychooncology. 2017 Sep;26(9):1361-1368. doi: 10.1002/pon.4148. Epub 2016 May 3.

49.

The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis.

Thomas AZ, Adibi M, Slack RS, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA.

J Urol. 2016 Sep;196(3):678-84. doi: 10.1016/j.juro.2016.03.144. Epub 2016 Mar 29.

50.

The use of spine stereotactic radiosurgery for oligometastatic disease.

Ho JC, Tang C, Deegan BJ, Allen PK, Jonasch E, Amini B, Wang XA, Li J, Tatsui CE, Rhines LD, Brown PD, Ghia AJ.

J Neurosurg Spine. 2016 Aug;25(2):239-47. doi: 10.3171/2016.1.SPINE151166. Epub 2016 Apr 1.

PMID:
27035507

Supplemental Content

Loading ...
Support Center